Regeneron 'mountain' gene therapy effort in potential $640M eye deal with Avalanche
By Randy Osborne
Monday, May 5, 2014
As investors await Regeneron Pharmaceuticals Inc.'s first quarter earnings, the company disclosed an ophthalmology deal with gene therapy specialist Avalanche Biotechnologies Inc. that buys a time-limited right to first negotiations to phase II-stage AVA-101, targeting VEGF for wet AMD.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.